The meeting aims to address the current challenges and opportunities that face the global development of Traditional Chinese Medicine (TCM).

The programme has been designed to address the key areas that impact TCM:

- Availability and quality of the genetic resources used in TCM
- Regulatory environment associated with modern drug development
- Advances in analytical technique that further our understanding of the complex mixtures used in TCM
- Standardization – quality and safety of TCM
- New guidelines of, and evidence from, clinical studies
- Integration of acupuncture

Aims of conference:

1. To provide an overview of new methods that can be used to enhance our knowledge about plants and fungi used in TCM.
2. To identify what evidence is needed to further the development of TCM in the West.
3. To identify key issues associated with the supply and quality of plants and fungi used in TCM and how this could be improved.
4. What are the regulatory challenges that TCM faces in the East and West and how could these be addressed?
5. What are the commercial opportunities for quality TCM products in China and the West: how can scientists help?
Wednesday 4 July, RBG Kew

08.30 Registration and refreshments

10.00 Opening address

Chairied by Professor Monique Simmonds, Deputy Director of Science (RBG Kew)
5–10 minutes each

Professor Kathy Willis, Director of Science (RBG Kew)
Dr Tai-Ping Fan, President GP-TCM RA (Cambridge University)

10.20 Keynote lecture (chaired by Professor Peter Hylands, Kings College London)

Professor De-an Guo (Shanghai Institute of Materia Medica)
‘Setting the scene: To provide an overview of the challenges and opportunities facing TCM’

11.00 Session 1: Special Interest Groups

Chaired by Professor Rudolf Bauer (Karl Franzens Universität)

Introduce the Special Interest Groups; Each special interest group to set the scene as to what they think are the big challenges that TCM researchers should be addressing

11.05 Professor Gerhard Franz (Universität Regensburg), Chair of Regulatory Aspects Special Interest Group

11.20 Professor Kelvin Chan (Liverpool John Moores University), Chair of Quality Control Special Interest Group

11.35 Professor Pierre Duez (Université de Mons), Chair of the Pharmacology and Toxicology Special Interest Group

11.50 Professor Nicola Robinson (LSBU), Chair of Acupuncture Special Interest Group

12.05 Professor Zhaoxiang Bian (Hong Kong Baptist University), Chair of Clinical Studies Special Interest Group

12.20 Lunch break

Opportunity to look at posters or attend workshop on ‘writing scientific papers’
Professor Robert Verpoorte (Leiden University)

14.00 Session 2: Special Interest Group Regulatory Aspects

Chaired by Professor Gerhard Franz (Universität Regensburg)

Question. Can we integrate the regulations for TCM in the West and East – and if not why not?

14.05 Keynote lecture – Dr Mei Wang (Leiden University, Netherlands)

‘Challenges and opportunities for TCM in Europe’

14.30 TBC
Thursday 5 July, RBG Kew

8.30  **Session 3: A celebration of Li Shizhen’s birth in 1518**
Chair by Dr Qihe Xu (Kings College London)

**Keynote lecture** – Professor Zhongzhen Zhao (Hong Kong Baptist University)
‘From Li Shizhen to now and our future’

9.00  **Session 4: Pharmacology and Toxicology Special Interest Group**
Chair by Professor Pierre Duez (Université de Mons)

**Question**: Is there a difference between pharmacology and toxicology or is it a matter of dose?

9.05  **Keynote lecture** – Professor Clara Lau (The Chinese University of Hong Kong)
‘New concept of ‘good practice’ on pharmacological research – exploration of beneficial herb-drug combined efficacies’

9.30  Professor Gert Laekeman (KU Leuven, Belgium)
‘Safety Pharmacology of Herbal Products’

9.50  Dr Andreas Bender (Cambridge University)
‘Chemogenomics to study pharmacology and toxicology of medicinal plants’

10.10  Discussion

10.40  **Refreshment break**

11.00  **Session 5: Quality Control Special Interest Group**
Chair by Professor Kelvin Chan (Liverpool John Moores University)

**Question**: From traditional ‘dry herbs’ to granules: what are the quality control challenges and how do we deal with them?

11.05  **Keynote lecture** – Professor Pang Chui Shaw (Chinese University of Hong Kong)
‘Use of DNA techniques in the identification of granule extracts’

11.25  Professor Shao-Ping Li (University of Macau)
‘Quality control of polysaccharides from medicinal plants and fungi’
11.40 Professor Lie-Fen Shyr (Agricultural Biotechnology Research Center, Academia Sinica, Taiwan)

‘From bench top to bed side: quality control of medicinal herbal products for human use’

12.00 Discussion

12.30 Lunch break

Opportunity to look at posters or attend workshop on Guidance Best Practice and Reference Resources: ‘Medicinal plant names’ (Dr Bob Allkin, RBG Kew)

14.00 Session 6: Conservation and sustainable supply

Chaired by Professor Vivian Wong, (The University of Hong Kong)

Question: Can demand be met?

14.05 Keynote lecture – Dr Christine Leon (RBG Kew)

‘A sustainable future for TCM plants and materia medica. Is it achievable?’

14.25 Professor Cheng Peng (Chengdu University of TCM, Chengdu, China)

‘Construction of National Germplasm Repository of Chinese Medicinal Materials and Research on Chinese Medicine Resources’

14.40 Dr Anastasiya Timoshyna (Traffic, Cambridge)

‘Sustainability, livelihoods and health: implementing best practices for wild-harvesting and trade in plants’

14.55 Discussion

15.25 Session 7: From plants to products

Chaired by Dr Tai-Ping Fan (Cambridge University)

Question: Can the scientific community help and if so how?

15.30 Mr Abraham Chan (PuraPharm International Hong Kong)

‘Opportunities for companies in the area of TCM – China: Modernization of Chinese Medicine’

15.50 Mr Andrew Gallagher (Phynova, UK)

‘Phynova case study: Modern healthcare solutions from ancient remedies’

16.10 Refreshment break

16.40 Actions going forward (chaired by Professors Monique Simmonds RBG Kew and Rudolf Bauer Karl Franzens Universität) Bring all the chairs of the Special Interest Groups along with keynote lectures together.

‘What next for TCM in the West – key objectives’

17.40 Poster Prizes and Closing remarks for the Kew days

Professor Nicola Robinson (LSBU) to set the science for next day in London.

18.30 Drinks reception

20.30 Depart
Friday 6 July, London South Bank University (LSBU)

8.30  Registration and refreshments

9.10  Welcome to LSBU – Professor Paul Ivey Pro VC Research and Engagement, Professor Warren Turner Dean Pro VC Health and Social Care, Professor Lesley Haig, Head of Allied Health Sciences

9.20  **Session 8: Acupuncture Special Interest Group**

Chaired by Professor Nicola Robinson (Professor of Traditional Chinese Medicine and Integrated Health, LSBU, and Chair: Acupuncture Special Interest Group)

**Question:** ‘The importance of International Collaborations’

9.30  **Keynote lecture** – Dr Stephen Birch (Kristiania University College, Oslo, Norway)

‘The effectiveness of acupuncture: evidence of extensive real-world clinical interpretations and applications’

10.00  Mr Mark Bovey (British Acupuncture Council, UK)

‘An overview of UK acupuncture research’

10.20  Dr John Hughes (Royal London Hospital for Integrated Medicine, University College London)

‘Improving the quality of acupuncture at the Royal London Hospital for Integrated Medicine’

10.40  **Refreshment break**

11.00  Professor Myeong Soo Lee (Korea Institute of Oriental Medicine, South Korea and Co-Chair: Clinical Studies Special Interest Group)

‘Acupuncture in sham device-controlled trials may not be as effective as acupuncture in clinical practice: a preliminary network meta-analysis’

11.20  Mr Ian Appleyard (LSBU, London)

*Acupuncture and the placebo*

11.40  Professor Jianping Liu (Beijing University of Chinese Medicine, China, and Co-Chair: Acupuncture Special Interest Group)

‘Lessons learned from conducting Chinese acupuncture trials’

12.40  Discussion and panel debate – Acupuncture research: Speakers/panel members

‘Where next? What evidence is good enough?’

13.10  **Lunch break**

14.00  **Session 9: Clinical Studies Special Interest Group**

Chaired by Professor Zhaoxiang Bian (Professor in Chinese Medicine, Director of Hong Kong Chinese Medicine Clinical Study Centre, Hong Kong Baptist University, and Chair: Lead of Clinical Studies Special Interest Group)

**Question:** What evidence do we need to show they work?

14.05  **Keynote lecture** – Professor Lixing Lao (The University of Hong Kong, Co-Chair: Acupuncture Special Interest Group)
‘Challenges and opportunities in Chinese medicine clinical trials’

14.25 Keynote lecture – Professor Aiping Lyu (Hong Kong Baptist University)
‘Disease diagnosis in western medicine and pattern classification in Chinese medicine: integration and beyond’

14.50 Refreshment break

15.10 Dr Jue Zhou (University College London and Zhejiang Gongshang University, Hangzhou, China)
‘The use of Chinese Medicine in treating gynaecological disorders’

15.30 Dr Martin Logue (University of Southampton)
‘Trials and Tribulations of Conducting UK Herbal Medicine Trials’

16.10 Discussion and panel debate
What are the opportunities for international collaborations in Clinical Studies?

16.40 Conclusion and closing remarks
Dr Tai-Ping (Cambridge University) and Professor Aiping Lyu (Hong Kong Baptist University)

16.50 End of event

This conference aims to contribute to many of the objectives of GP-TCM RA.

The Association is a non-for-profit organisation dedicated to promoting high-quality evidence-based research of traditional Chinese medicine (TCM) through developing, disseminating and implementing good practice. The objectives for which the Association is established are:

1. Perpetuate the interactive network established by the FP7 GP-TCM consortium;
2. Promote discussion and implementation of good practice in TCM research and development, including the use of sustainably sourced materials;
3. Advocate high-quality evidence-based research and development on TCM as well as on its integration with conventional medicine;
4. Organise and co-organise scientific meetings and specialist courses;
5. Nurture young TCM researchers at different levels in an interdisciplinary approach, including BSc, MSc, PhD and post-doctoral programmes;
6. Facilitate collaborations and sharing of resources, expertise and good practice among members, industry and regulatory agencies;
7. Encourage collaborations with existing relevant societies, consortia and organisations;
8. Strengthen interdisciplinary, interregional, and intersectoral collaborations in TCM research and development;
9. Perpetuate good practice in publishing TCM research outcomes;
10. Disseminate scientific research outcomes and latest developments in regulatory sciences to stakeholders, industry, professional groups and the public.